Construction of a More Effective Conditional Replication-Competent Adenoviral Vectors Targeting Liver Cancer and Its Cancerostatic Effect in Vitro

FU Qiang,WANG Hui-ping,WEI Fang,LI Hui-ming,CHEN Xia-fang,WANG Yu-fei,HUANG Qian
2009-01-01
Abstract:Objective:To construct two conditional replication-competent adenoviral vectors (CRAs) driven by alpha fetoprotein (AFP)300bp promoter and 300bp promoter+AFP 800bp enhancer respectively,and to find a better CRA vector for liver cancer targeting therapy. Methods:The minimal essential DNA fragment of the AFP gene promoter and enhancer was amplified through PCR from the genome of HepG2 cells. Construct the plasmid pAFPp-EGFPluc and pAFPep-EGFPluc to evaluate the activity of the AFP promoter and enhancer by the way of flow cytometry and detect fluorescence. Then construct the shuttle plasmid pDC311-AFPp-E1A and pDC311-AFPep-E1A and construct the conditional replicative adnovirus (CRAs)Ad.AFPp-E1A and Ad.AFPep-E1A. The ability of conditional replication was detected and compared by western blot, virus multiplication test and CPE. At last measure the oncolytic efficacy of these two viruses in AFP positive cells like HepG2 and Hep3B. Results: Both AFPp-E1A and Ad.AFPep-E1A could be selectively replicated in AFP positive cells and could be selectively inhibited AFP positive cells and the latter adenovirus was better. After using Ad. AFPp-E1A, the survival rates of HepG2 and Hep3B were (54.23±7.13)% and (61.18±12.63)% respectively. After using Ad. AF Pep-E1A, the survival rates of HepG2 and Hep3B were (26.65±5.43)% and (24.49±3.31)% respectively. Conclusions:We use the short AFP 800bp enhancer for the first time.It can enhance the activity of AFP promoter,at the same time, it provides more room to add more therapy gene for adenovirus package. Thereby,Ad.AFPep-E1A is a promising vector candidate for hepatocarcinoma targeting therapy.
What problem does this paper attempt to address?